ORTHO-GYNOL CONTRACEPTIVE JELLY LABELING WILL BE UNCHANGED in the wake of a Supreme Court ruling to let stand a $4.7 mil. damage award against Ortho for birth defects allegedly caused by the contraceptive. Current labeling for the contraceptive does not warn against birth defects. Ortho maintains that there is no scientific evidence linking Ortho-Gynol to birth defects. FDA's Fertility and Maternal Health Drugs Advisory Committee reviewed safety data on vaginal spermicides at its December 1983 meeting. At that time, the committee concluded that existing evidence did not support a link between fetal abnormalities and use of spermicides, and recommended that the products not be labeled to warn against use during pregnancy. Ortho said the recent damage ruling is the first time the company has been held liable for damages related to its spermicide product. Ortho said three Ortho-Gynol liability cases against the company are currently pending.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”
The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.
Experts from EUCOPE explain why the Council of the EU’s position on the proposed overhaul of the general pharmaceutical legislation could offer more predictability for companies than the commission’s initial offering.
